Program
Anti-mesothelin Antibody-drug Conjugate SGN-MesoC2
In Pfizer’s pipeline, mesothelin-targeted antibody-drug conjugate
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Pfizer.
Furthest: phase 1, since Jun 11, 20241 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 10 open or running | phase 1since Jun 11, 2024 | Jun 11, 2024 | none ahead |
- Named in Pfizer’s own pipeline as
PF-08052666
, phase 1, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 11, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06466187 · 19 enrolled · United States, Canada
TargetBeta
“mesothelin-targeted antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cell surface glycoprotein and tumor-associated antigen (TAA) mesothelin (MSLN) and conjugated, via a tumor-specific cleavable linker, to a topoisomerase-1 inhibitor (TOP1i), with potential antineoplastic…”NCIt, read by Claude
Other programs on MSLN
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101rule | outpace-bio-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06466187Carcinoma, Non-Small-Cell Lung · United States, Canada | 1 | Terminated | May 27, 2026 | 19 |
How it is read
Names in the registry
- “PF-08052666”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.